Tuberculosis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：286頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Tuberculosis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Tuberculosis - Pipeline Review, H1 2014’, provides an overview of the Tuberculosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Tuberculosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Tuberculosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Tuberculosis - Pipeline Review, H1 2014’, provides an overview of the Tuberculosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Tuberculosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Tuberculosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Tuberculosis Overview 11
Therapeutics Development 12
Pipeline Products for Tuberculosis - Overview 12
Pipeline Products for Tuberculosis - Comparative Analysis 13
Tuberculosis - Therapeutics under Development by Companies 14
Tuberculosis - Therapeutics under Investigation by Universities/Institutes 20
Tuberculosis - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Tuberculosis - Products under Development by Companies 28
Tuberculosis - Products under Investigation by Universities/Institutes 33
Tuberculosis - Companies Involved in Therapeutics Development 36
Johnson & Johnson 36
Sequella, Inc. 37
Sanofi 38
AstraZeneca PLC 39
Eli Lilly and Company 40
GlaxoSmithKline plc 41
Imaxio 42
FIT Biotech Oyj 43
Piramal Enterprises Limited 44
Novartis AG 45
Achillion Pharmaceuticals, Inc. 46
Eisai Co., Ltd. 47
Vertex Pharmaceuticals Incorporated 48
Sarepta Therapeutics, Inc. 49
Crucell N.V. 50
BioDiem Ltd 51
Transgene SA 52
Snowdon Inc. 53
ImmunoBiology Ltd. 54
Recipharm AB 55
Dafra Pharma International Ltd. 56
Anacor Pharmaceuticals, Inc. 57
PT Bio Farma 58
MicuRx Pharmaceuticals, Inc. 59
Therametrics holding AG 60
Okairos AG 61
EpiVax, Inc. 62
Archivel Farma S.L. 63
Chimerix, Inc. 64
Pharminox Limited 65
Immunovaccine, Inc. 66
Globeimmune, Inc. 67
Genticel 68
Canopus BioPharma Incorporated 69
Cellceutix Corporation 70
TVAX Biomedical, Inc. 71
Medisyn Technologies, Inc. 72
Vakzine Projekt Management GmbH 73
Ensoltek Co., Ltd. 74
B&C Biopharm 75
NeED Pharma s.r.l. 76
Otsuka Holdings Co., Ltd. 77
Vichem Chemie Research Ltd. 78
Lipotek Pty Ltd. 79
Vaxil Bio Therapeutics Ltd. 80
Sphaera Pharma Pvt. Ltd. 81
Microbion Corporation 82
Chongqing Zhifei Biological Products Co., Ltd. 83
Immunitor, Inc. 84
Bioversys AG 85
Valneva SE 86
GlobalAcorn 87
Abera Bioscience AB 88
Pharmapraxis 89
Tuberculosis - Therapeutics Assessment 90
Assessment by Monotherapy Products 90
Assessment by Target 91
Assessment by Mechanism of Action 94
Assessment by Route of Administration 97
Assessment by Molecule Type 99
Drug Profiles 102
delamanid - Drug Profile 102
delamanid - Drug Profile 104
V-7 Vaccine - Drug Profile 106
SQ-109 - Drug Profile 108
delamanid - Drug Profile 110
Tuberculosis Vaccine - Drug Profile 112
sutezolid - Drug Profile 113
VPM-1002 - Drug Profile 114
GSK-692342 - Drug Profile 115
Crucell Ad-35 - Drug Profile 117
RUTI Vaccine - Drug Profile 119
SSI H56-IC31 Vaccine - Drug Profile 120
AERAS-422 Vaccine - Drug Profile 122
IMX-313-TB - Drug Profile 123
Ad5Ag85A Vaccine - Drug Profile 124
PMX-10072 - Drug Profile 125
NasL3/HtkBCG Vaccine - Drug Profile 126
MTBVAC01 - Drug Profile 127
Ac2SGL Diacylated Sulfoglycolipid Vaccine - Drug Profile 128
HG-85A/B - Drug Profile 129
HG856-A - Drug Profile 130
HG856-BCG - Drug Profile 131
R32Kda-BCG Vaccine - Drug Profile 132
AERAS-Capsid Vaccine - Drug Profile 133
HBHA Vaccine - Drug Profile 134
Streptomyces Live Vector Vaccine - Drug Profile 135
rBCG(mbtB)30 Vaccine - Drug Profile 136
NasL3/AM85B Vaccine - Drug Profile 137
paBCG Vaccine - Drug Profile 138
ORT-VAC DNA Vaccine - Drug Profile 139
DasKloster-024901 - Drug Profile 140
MTbuVax - Drug Profile 141
TVI-Tuberculosis-1 - Drug Profile 142
T-Biovax - Drug Profile 143
PM-181108 - Drug Profile 145
BDM-I - Drug Profile 146
Mtb Vaccine - Drug Profile 147
HG-85A - Drug Profile 148
LIP1 Ac2SGL Sulfoglycolipid Vaccine - Drug Profile 149
Latency Fusion Proteins Based Vaccine - Drug Profile 150
Recombinant LCMV Vaccine - Drug Profile 151
pUMVC6/7 DNA Vaccine - Drug Profile 152
IKEPLUS Vaccine - Drug Profile 153
DNAacr Vaccine - Drug Profile 154
S006-830 - Drug Profile 155
TBA-354 - Drug Profile 156
TB Therapeutic Vaccine - Drug Profile 157
mepenzolate bromide - Drug Profile 158
CPZEN-45 - Drug Profile 159
ND-801 - Drug Profile 160
TB-10.4 - Drug Profile 161
AKT-10081 - Drug Profile 162
BT Compound Systemic - Drug Profile 163
Enoyl Reductase Inhibitors for Infectious Diseases - Drug Profile 164
Tuberculosis Vaccine - Drug Profile 165
Q-203 - Drug Profile 166
Vaccine For Tuberculosis - Drug Profile 167
Anti-Connection Drug - Drug Profile 168
Tuberculosis Vaccine Program - Drug Profile 169
Pam2Cys Vaccine - Drug Profile 170
TBI-166 - Drug Profile 171
TCA-1 - Drug Profile 172
Small Molecules for Tuberculosis - Drug Profile 173
Small Molecules for Tuberculosis - Drug Profile 174
Cyclopeptides - Drug Profile 175
S-0081167 - Drug Profile 176
S-008-1635 - Drug Profile 177
S009-895 - Drug Profile 178
S-0100399 - Drug Profile 179
Tuberculosis Vaccine - Drug Profile 180
GI-19000 - Drug Profile 181
SND-159 - Drug Profile 182
PS-Conjugate Vaccine - Drug Profile 183
Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile 184
Mycobacterial Liposomes And Proteosomal Vaccine - Drug Profile 185
Small Molecules for Tuberculosis - Drug Profile 186
FP6 TBVAC - Drug Profile 187
Anti-Bacterial Program - Drug Profile 189
PMX-10070 - Drug Profile 190
PMX-30053 - Drug Profile 191
Drug For Tuberculosis - Drug Profile 192
Bacterial PPMO - Drug Profile 193
MicroRNA-Like Molecules - Drug Profile 194
PMX-464 - Drug Profile 195
Tuberculosis Program - Drug Profile 196
Multi-Epitope Tuberculosis Vaccine - Drug Profile 198
TB Vaccine - Drug Profile 199
LIP2 SL37 (Synthetic) Sulfoglycolipid Vaccine - Drug Profile 200
Small Molecules For Tuberculosis - Drug Profile 201
Small Molecules for Infectious Diseases - Drug Profile 202
Anti-Tuberculosis Program - Drug Profile 203
ND-701 - Drug Profile 204
ND-201 - Drug Profile 205
ND-601 - Drug Profile 206
Small Molecules to Inhibit InhA for Tuberculosis - Drug Profile 207
VI-15910 - Drug Profile 208
ebselen - Drug Profile 209
Subunit Vaccine for Tuberculosis - Drug Profile 210
NM-031 - Drug Profile 211
MDR And XDR Tuberculosis Program - Drug Profile 212
Small Molecules for Bacterial Infections - Drug Profile 213
Drug for Infectious Diseases - Drug Profile 214
Small Molecule to Inhibit RNA Polymerase for Bacterial Infections - Drug Profile 215
Compound-6 - Drug Profile 216
Compound-5 - Drug Profile 217
Myxopyronin Analogs - Drug Profile 218
VI-18469 - Drug Profile 219
VI-9376 - Drug Profile 220
AX-20017 - Drug Profile 221
VI-14585 - Drug Profile 222
VI-15843 - Drug Profile 223
Sharon-1000 - Drug Profile 224
Tuberculosis Vaccine - Drug Profile 225
Drug to Inhibit DNA Gyrase for Tuberculosis - Drug Profile 226
Small Molecules for Tuberculosis - Drug Profile 227
Small Molecules to Inhibit Pantothenate Synthetase for Tuberculosis and Bacterial Infections - Drug Profile 228
Small Molecules Inhibiting Leucyl-tRNA Synthetase For Tuberculosis - Drug Profile 229
Diarylquinolines - Drug Profile 230
Drug to Inhibit DprE for Tuberculosis - Drug Profile 231
Macrolides - Drug Profile 232
Small Molecules to Inhibit RNA Polymerase for Tuberculosis - Drug Profile 233
BVTB-2 - Drug Profile 234
Tuberculosis Program - Drug Profile 235
Pleuromutilin Analogs - Drug Profile 236
TB-001 - Drug Profile 237
GA-3-MEP-TB - Drug Profile 238
GA-4-NM-TB - Drug Profile 239
Small Molecules For Tuberculosis - Drug Profile 240
Tuberculosis Program - Drug Profile 241
Drug for Tuberculosis - Drug Profile 242
Drug Candidates for Nematodal Diseases and TB - Drug Profile 243
DF-152 Series - Drug Profile 244
Small molecules for Tuberculosis - Drug Profile 245
HG856-SeV - Drug Profile 246
CB-2009 - Drug Profile 247
CB-3900 - Drug Profile 248
Lipovaxin-TB - Drug Profile 249
Drug For Tuberculosis - Drug Profile 250
Human Liporale-BCG Vaccine - Drug Profile 251
Multi-Drug Resistant Tuberculosis Program - Drug Profile 252
Tuberculosis Vaccine - Drug Profile 253
Tuberculosis - Recent Pipeline Updates 254
Tuberculosis - Dormant Projects 264
Tuberculosis - Discontinued Products 265
Tuberculosis - Product Development Milestones 266
Featured News & Press Releases 266
Appendix 275
Methodology 275
Coverage 275
Secondary Research 275
Primary Research 275
Expert Panel Validation 275
Contact Us 276
Disclaimer 276
List of Tables
Number of Products under Development for Tuberculosis, H1 2014 22
Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 25
Number of Products under Development by Companies, H1 2014 (Contd..1) 26
Number of Products under Development by Companies, H1 2014 (Contd..2) 27
Number of Products under Development by Companies, H1 2014 (Contd..3) 28
Number of Products under Development by Companies, H1 2014 (Contd..4) 29
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 32
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 33
Comparative Analysis by Late Stage Development, H1 2014 34
Comparative Analysis by Clinical Stage Development, H1 2014 35
Comparative Analysis by Early Stage Development, H1 2014 36
Comparative Analysis by Unknown Stage Development, H1 2014 37
Products under Development by Companies, H1 2014 38
Products under Development by Companies, H1 2014 (Contd..1) 39
Products under Development by Companies, H1 2014 (Contd..2) 40
Products under Development by Companies, H1 2014 (Contd..3) 41
Products under Development by Companies, H1 2014 (Contd..4) 42
Products under Investigation by Universities/Institutes, H1 2014 43
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 44
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 45
Tuberculosis - Pipeline by Johnson & Johnson, H1 2014 46
Tuberculosis - Pipeline by Sequella, Inc., H1 2014 47
Tuberculosis - Pipeline by Sanofi, H1 2014 48
Tuberculosis - Pipeline by AstraZeneca PLC, H1 2014 49
Tuberculosis - Pipeline by Eli Lilly and Company, H1 2014 50
Tuberculosis - Pipeline by GlaxoSmithKline plc, H1 2014 51
Tuberculosis - Pipeline by Imaxio, H1 2014 52
Tuberculosis - Pipeline by FIT Biotech Oyj, H1 2014 53
Tuberculosis - Pipeline by Piramal Enterprises Limited, H1 2014 54
Tuberculosis - Pipeline by Novartis AG, H1 2014 55
Tuberculosis - Pipeline by Achillion Pharmaceuticals, Inc., H1 2014 56
Tuberculosis - Pipeline by Eisai Co., Ltd., H1 2014 57
Tuberculosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 58
Tuberculosis - Pipeline by Sarepta Therapeutics, Inc., H1 2014 59
Tuberculosis - Pipeline by Crucell N.V., H1 2014 60
Tuberculosis - Pipeline by BioDiem Ltd, H1 2014 61
Tuberculosis - Pipeline by Transgene SA, H1 2014 62
Tuberculosis - Pipeline by Snowdon Inc., H1 2014 63
Tuberculosis - Pipeline by ImmunoBiology Ltd., H1 2014 64
Tuberculosis - Pipeline by Recipharm AB, H1 2014 65
Tuberculosis - Pipeline by Dafra Pharma International Ltd., H1 2014 66
Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 67
Tuberculosis - Pipeline by PT Bio Farma, H1 2014 68
Tuberculosis - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2014 69
Tuberculosis - Pipeline by Therametrics holding AG, H1 2014 70
Tuberculosis - Pipeline by Okairos AG, H1 2014 71
Tuberculosis - Pipeline by EpiVax, Inc., H1 2014 72
Tuberculosis - Pipeline by Archivel Farma S.L., H1 2014 73
Tuberculosis - Pipeline by Chimerix, Inc., H1 2014 74
Tuberculosis - Pipeline by Pharminox Limited, H1 2014 75
Tuberculosis - Pipeline by Immunovaccine, Inc., H1 2014 76
Tuberculosis - Pipeline by Globeimmune, Inc., H1 2014 77
Tuberculosis - Pipeline by Genticel, H1 2014 78
Tuberculosis - Pipeline by Canopus BioPharma Incorporated, H1 2014 79
Tuberculosis - Pipeline by Cellceutix Corporation, H1 2014 80
Tuberculosis - Pipeline by TVAX Biomedical, Inc., H1 2014 81
Tuberculosis - Pipeline by Medisyn Technologies, Inc., H1 2014 82
Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H1 2014 83
Tuberculosis - Pipeline by Ensoltek Co., Ltd., H1 2014 84
Tuberculosis - Pipeline by B&C Biopharm, H1 2014 85
Tuberculosis - Pipeline by NeED Pharma s.r.l., H1 2014 86
Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 87
Tuberculosis - Pipeline by Vichem Chemie Research Ltd., H1 2014 88
Tuberculosis - Pipeline by Lipotek Pty Ltd., H1 2014 89
Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2014 90
Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2014 91
Tuberculosis - Pipeline by Microbion Corporation, H1 2014 92
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014 93
Tuberculosis - Pipeline by Immunitor, Inc., H1 2014 94
Tuberculosis - Pipeline by Bioversys AG, H1 2014 95
Tuberculosis - Pipeline by Valneva SE, H1 2014 96
Tuberculosis - Pipeline by GlobalAcorn, H1 2014 97
Tuberculosis - Pipeline by Abera Bioscience AB, H1 2014 98
Tuberculosis - Pipeline by Pharmapraxis, H1 2014 99
Assessment by Monotherapy Products, H1 2014 100
Number of Products by Stage and Target, H1 2014 103
Number of Products by Stage and Mechanism of Action, H1 2014 106
Number of Products by Stage and Route of Administration, H1 2014 108
Number of Products by Stage and Molecule Type, H1 2014 111
Tuberculosis Therapeutics - Recent Pipeline Updates, H1 2014 264
Tuberculosis - Dormant Projects, H1 2014 274
Tuberculosis - Discontinued Products, H1 2014 275
List of Figures
Number of Products under Development for Tuberculosis, H1 2014 22
Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 24
Number of Products under Investigation by Universities/Institutes, H1 2014 30
Comparative Analysis by Late Stage Development, H1 2014 34
Comparative Analysis by Clinical Stage Development, H1 2014 35
Comparative Analysis by Early Stage Products, H1 2014 36
Assessment by Monotherapy Products, H1 2014 100
Number of Products by Top 10 Target, H1 2014 101
Number of Products by Stage and Top 10 Target, H1 2014 102
Number of Products by Top 10 Mechanism of Action, H1 2014 104
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 105
Number of Products by Top 10 Route of Administration, H1 2014 107
Number of Products by Stage and Top 10 Route of Administration, H1 2014 108
Number of Products by Top 10 Molecule Type, H1 2014 109
Number of Products by Stage and Top 10 Molecule Type, H1 2014 110
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Tuberculosis Overview 11
Therapeutics Development 12
Pipeline Products for Tuberculosis - Overview 12
Pipeline Products for Tuberculosis - Comparative Analysis 13
Tuberculosis - Therapeutics under Development by Companies 14
Tuberculosis - Therapeutics under Investigation by Universities/Institutes 20
Tuberculosis - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Tuberculosis - Products under Development by Companies 28
Tuberculosis - Products under Investigation by Universities/Institutes 33
Tuberculosis - Companies Involved in Therapeutics Development 36
Johnson & Johnson 36
Sequella, Inc. 37
Sanofi 38
AstraZeneca PLC 39
Eli Lilly and Company 40
GlaxoSmithKline plc 41
Imaxio 42
FIT Biotech Oyj 43
Piramal Enterprises Limited 44
Novartis AG 45
Achillion Pharmaceuticals, Inc. 46
Eisai Co., Ltd. 47
Vertex Pharmaceuticals Incorporated 48
Sarepta Therapeutics, Inc. 49
Crucell N.V. 50
BioDiem Ltd 51
Transgene SA 52
Snowdon Inc. 53
ImmunoBiology Ltd. 54
Recipharm AB 55
Dafra Pharma International Ltd. 56
Anacor Pharmaceuticals, Inc. 57
PT Bio Farma 58
MicuRx Pharmaceuticals, Inc. 59
Therametrics holding AG 60
Okairos AG 61
EpiVax, Inc. 62
Archivel Farma S.L. 63
Chimerix, Inc. 64
Pharminox Limited 65
Immunovaccine, Inc. 66
Globeimmune, Inc. 67
Genticel 68
Canopus BioPharma Incorporated 69
Cellceutix Corporation 70
TVAX Biomedical, Inc. 71
Medisyn Technologies, Inc. 72
Vakzine Projekt Management GmbH 73
Ensoltek Co., Ltd. 74
B&C Biopharm 75
NeED Pharma s.r.l. 76
Otsuka Holdings Co., Ltd. 77
Vichem Chemie Research Ltd. 78
Lipotek Pty Ltd. 79
Vaxil Bio Therapeutics Ltd. 80
Sphaera Pharma Pvt. Ltd. 81
Microbion Corporation 82
Chongqing Zhifei Biological Products Co., Ltd. 83
Immunitor, Inc. 84
Bioversys AG 85
Valneva SE 86
GlobalAcorn 87
Abera Bioscience AB 88
Pharmapraxis 89
Tuberculosis - Therapeutics Assessment 90
Assessment by Monotherapy Products 90
Assessment by Target 91
Assessment by Mechanism of Action 94
Assessment by Route of Administration 97
Assessment by Molecule Type 99
Drug Profiles 102
delamanid - Drug Profile 102
delamanid - Drug Profile 104
V-7 Vaccine - Drug Profile 106
SQ-109 - Drug Profile 108
delamanid - Drug Profile 110
Tuberculosis Vaccine - Drug Profile 112
sutezolid - Drug Profile 113
VPM-1002 - Drug Profile 114
GSK-692342 - Drug Profile 115
Crucell Ad-35 - Drug Profile 117
RUTI Vaccine - Drug Profile 119
SSI H56-IC31 Vaccine - Drug Profile 120
AERAS-422 Vaccine - Drug Profile 122
IMX-313-TB - Drug Profile 123
Ad5Ag85A Vaccine - Drug Profile 124
PMX-10072 - Drug Profile 125
NasL3/HtkBCG Vaccine - Drug Profile 126
MTBVAC01 - Drug Profile 127
Ac2SGL Diacylated Sulfoglycolipid Vaccine - Drug Profile 128
HG-85A/B - Drug Profile 129
HG856-A - Drug Profile 130
HG856-BCG - Drug Profile 131
R32Kda-BCG Vaccine - Drug Profile 132
AERAS-Capsid Vaccine - Drug Profile 133
HBHA Vaccine - Drug Profile 134
Streptomyces Live Vector Vaccine - Drug Profile 135
rBCG(mbtB)30 Vaccine - Drug Profile 136
NasL3/AM85B Vaccine - Drug Profile 137
paBCG Vaccine - Drug Profile 138
ORT-VAC DNA Vaccine - Drug Profile 139
DasKloster-024901 - Drug Profile 140
MTbuVax - Drug Profile 141
TVI-Tuberculosis-1 - Drug Profile 142
T-Biovax - Drug Profile 143
PM-181108 - Drug Profile 145
BDM-I - Drug Profile 146
Mtb Vaccine - Drug Profile 147
HG-85A - Drug Profile 148
LIP1 Ac2SGL Sulfoglycolipid Vaccine - Drug Profile 149
Latency Fusion Proteins Based Vaccine - Drug Profile 150
Recombinant LCMV Vaccine - Drug Profile 151
pUMVC6/7 DNA Vaccine - Drug Profile 152
IKEPLUS Vaccine - Drug Profile 153
DNAacr Vaccine - Drug Profile 154
S006-830 - Drug Profile 155
TBA-354 - Drug Profile 156
TB Therapeutic Vaccine - Drug Profile 157
mepenzolate bromide - Drug Profile 158
CPZEN-45 - Drug Profile 159
ND-801 - Drug Profile 160
TB-10.4 - Drug Profile 161
AKT-10081 - Drug Profile 162
BT Compound Systemic - Drug Profile 163
Enoyl Reductase Inhibitors for Infectious Diseases - Drug Profile 164
Tuberculosis Vaccine - Drug Profile 165
Q-203 - Drug Profile 166
Vaccine For Tuberculosis - Drug Profile 167
Anti-Connection Drug - Drug Profile 168
Tuberculosis Vaccine Program - Drug Profile 169
Pam2Cys Vaccine - Drug Profile 170
TBI-166 - Drug Profile 171
TCA-1 - Drug Profile 172
Small Molecules for Tuberculosis - Drug Profile 173
Small Molecules for Tuberculosis - Drug Profile 174
Cyclopeptides - Drug Profile 175
S-0081167 - Drug Profile 176
S-008-1635 - Drug Profile 177
S009-895 - Drug Profile 178
S-0100399 - Drug Profile 179
Tuberculosis Vaccine - Drug Profile 180
GI-19000 - Drug Profile 181
SND-159 - Drug Profile 182
PS-Conjugate Vaccine - Drug Profile 183
Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile 184
Mycobacterial Liposomes And Proteosomal Vaccine - Drug Profile 185
Small Molecules for Tuberculosis - Drug Profile 186
FP6 TBVAC - Drug Profile 187
Anti-Bacterial Program - Drug Profile 189
PMX-10070 - Drug Profile 190
PMX-30053 - Drug Profile 191
Drug For Tuberculosis - Drug Profile 192
Bacterial PPMO - Drug Profile 193
MicroRNA-Like Molecules - Drug Profile 194
PMX-464 - Drug Profile 195
Tuberculosis Program - Drug Profile 196
Multi-Epitope Tuberculosis Vaccine - Drug Profile 198
TB Vaccine - Drug Profile 199
LIP2 SL37 (Synthetic) Sulfoglycolipid Vaccine - Drug Profile 200
Small Molecules For Tuberculosis - Drug Profile 201
Small Molecules for Infectious Diseases - Drug Profile 202
Anti-Tuberculosis Program - Drug Profile 203
ND-701 - Drug Profile 204
ND-201 - Drug Profile 205
ND-601 - Drug Profile 206
Small Molecules to Inhibit InhA for Tuberculosis - Drug Profile 207
VI-15910 - Drug Profile 208
ebselen - Drug Profile 209
Subunit Vaccine for Tuberculosis - Drug Profile 210
NM-031 - Drug Profile 211
MDR And XDR Tuberculosis Program - Drug Profile 212
Small Molecules for Bacterial Infections - Drug Profile 213
Drug for Infectious Diseases - Drug Profile 214
Small Molecule to Inhibit RNA Polymerase for Bacterial Infections - Drug Profile 215
Compound-6 - Drug Profile 216
Compound-5 - Drug Profile 217
Myxopyronin Analogs - Drug Profile 218
VI-18469 - Drug Profile 219
VI-9376 - Drug Profile 220
AX-20017 - Drug Profile 221
VI-14585 - Drug Profile 222
VI-15843 - Drug Profile 223
Sharon-1000 - Drug Profile 224
Tuberculosis Vaccine - Drug Profile 225
Drug to Inhibit DNA Gyrase for Tuberculosis - Drug Profile 226
Small Molecules for Tuberculosis - Drug Profile 227
Small Molecules to Inhibit Pantothenate Synthetase for Tuberculosis and Bacterial Infections - Drug Profile 228
Small Molecules Inhibiting Leucyl-tRNA Synthetase For Tuberculosis - Drug Profile 229
Diarylquinolines - Drug Profile 230
Drug to Inhibit DprE for Tuberculosis - Drug Profile 231
Macrolides - Drug Profile 232
Small Molecules to Inhibit RNA Polymerase for Tuberculosis - Drug Profile 233
BVTB-2 - Drug Profile 234
Tuberculosis Program - Drug Profile 235
Pleuromutilin Analogs - Drug Profile 236
TB-001 - Drug Profile 237
GA-3-MEP-TB - Drug Profile 238
GA-4-NM-TB - Drug Profile 239
Small Molecules For Tuberculosis - Drug Profile 240
Tuberculosis Program - Drug Profile 241
Drug for Tuberculosis - Drug Profile 242
Drug Candidates for Nematodal Diseases and TB - Drug Profile 243
DF-152 Series - Drug Profile 244
Small molecules for Tuberculosis - Drug Profile 245
HG856-SeV - Drug Profile 246
CB-2009 - Drug Profile 247
CB-3900 - Drug Profile 248
Lipovaxin-TB - Drug Profile 249
Drug For Tuberculosis - Drug Profile 250
Human Liporale-BCG Vaccine - Drug Profile 251
Multi-Drug Resistant Tuberculosis Program - Drug Profile 252
Tuberculosis Vaccine - Drug Profile 253
Tuberculosis - Recent Pipeline Updates 254
Tuberculosis - Dormant Projects 264
Tuberculosis - Discontinued Products 265
Tuberculosis - Product Development Milestones 266
Featured News & Press Releases 266
Appendix 275
Methodology 275
Coverage 275
Secondary Research 275
Primary Research 275
Expert Panel Validation 275
Contact Us 276
Disclaimer 276
List of Tables
Number of Products under Development for Tuberculosis, H1 2014 22
Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 25
Number of Products under Development by Companies, H1 2014 (Contd..1) 26
Number of Products under Development by Companies, H1 2014 (Contd..2) 27
Number of Products under Development by Companies, H1 2014 (Contd..3) 28
Number of Products under Development by Companies, H1 2014 (Contd..4) 29
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 32
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 33
Comparative Analysis by Late Stage Development, H1 2014 34
Comparative Analysis by Clinical Stage Development, H1 2014 35
Comparative Analysis by Early Stage Development, H1 2014 36
Comparative Analysis by Unknown Stage Development, H1 2014 37
Products under Development by Companies, H1 2014 38
Products under Development by Companies, H1 2014 (Contd..1) 39
Products under Development by Companies, H1 2014 (Contd..2) 40
Products under Development by Companies, H1 2014 (Contd..3) 41
Products under Development by Companies, H1 2014 (Contd..4) 42
Products under Investigation by Universities/Institutes, H1 2014 43
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 44
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 45
Tuberculosis - Pipeline by Johnson & Johnson, H1 2014 46
Tuberculosis - Pipeline by Sequella, Inc., H1 2014 47
Tuberculosis - Pipeline by Sanofi, H1 2014 48
Tuberculosis - Pipeline by AstraZeneca PLC, H1 2014 49
Tuberculosis - Pipeline by Eli Lilly and Company, H1 2014 50
Tuberculosis - Pipeline by GlaxoSmithKline plc, H1 2014 51
Tuberculosis - Pipeline by Imaxio, H1 2014 52
Tuberculosis - Pipeline by FIT Biotech Oyj, H1 2014 53
Tuberculosis - Pipeline by Piramal Enterprises Limited, H1 2014 54
Tuberculosis - Pipeline by Novartis AG, H1 2014 55
Tuberculosis - Pipeline by Achillion Pharmaceuticals, Inc., H1 2014 56
Tuberculosis - Pipeline by Eisai Co., Ltd., H1 2014 57
Tuberculosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 58
Tuberculosis - Pipeline by Sarepta Therapeutics, Inc., H1 2014 59
Tuberculosis - Pipeline by Crucell N.V., H1 2014 60
Tuberculosis - Pipeline by BioDiem Ltd, H1 2014 61
Tuberculosis - Pipeline by Transgene SA, H1 2014 62
Tuberculosis - Pipeline by Snowdon Inc., H1 2014 63
Tuberculosis - Pipeline by ImmunoBiology Ltd., H1 2014 64
Tuberculosis - Pipeline by Recipharm AB, H1 2014 65
Tuberculosis - Pipeline by Dafra Pharma International Ltd., H1 2014 66
Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 67
Tuberculosis - Pipeline by PT Bio Farma, H1 2014 68
Tuberculosis - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2014 69
Tuberculosis - Pipeline by Therametrics holding AG, H1 2014 70
Tuberculosis - Pipeline by Okairos AG, H1 2014 71
Tuberculosis - Pipeline by EpiVax, Inc., H1 2014 72
Tuberculosis - Pipeline by Archivel Farma S.L., H1 2014 73
Tuberculosis - Pipeline by Chimerix, Inc., H1 2014 74
Tuberculosis - Pipeline by Pharminox Limited, H1 2014 75
Tuberculosis - Pipeline by Immunovaccine, Inc., H1 2014 76
Tuberculosis - Pipeline by Globeimmune, Inc., H1 2014 77
Tuberculosis - Pipeline by Genticel, H1 2014 78
Tuberculosis - Pipeline by Canopus BioPharma Incorporated, H1 2014 79
Tuberculosis - Pipeline by Cellceutix Corporation, H1 2014 80
Tuberculosis - Pipeline by TVAX Biomedical, Inc., H1 2014 81
Tuberculosis - Pipeline by Medisyn Technologies, Inc., H1 2014 82
Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H1 2014 83
Tuberculosis - Pipeline by Ensoltek Co., Ltd., H1 2014 84
Tuberculosis - Pipeline by B&C Biopharm, H1 2014 85
Tuberculosis - Pipeline by NeED Pharma s.r.l., H1 2014 86
Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 87
Tuberculosis - Pipeline by Vichem Chemie Research Ltd., H1 2014 88
Tuberculosis - Pipeline by Lipotek Pty Ltd., H1 2014 89
Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2014 90
Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2014 91
Tuberculosis - Pipeline by Microbion Corporation, H1 2014 92
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014 93
Tuberculosis - Pipeline by Immunitor, Inc., H1 2014 94
Tuberculosis - Pipeline by Bioversys AG, H1 2014 95
Tuberculosis - Pipeline by Valneva SE, H1 2014 96
Tuberculosis - Pipeline by GlobalAcorn, H1 2014 97
Tuberculosis - Pipeline by Abera Bioscience AB, H1 2014 98
Tuberculosis - Pipeline by Pharmapraxis, H1 2014 99
Assessment by Monotherapy Products, H1 2014 100
Number of Products by Stage and Target, H1 2014 103
Number of Products by Stage and Mechanism of Action, H1 2014 106
Number of Products by Stage and Route of Administration, H1 2014 108
Number of Products by Stage and Molecule Type, H1 2014 111
Tuberculosis Therapeutics - Recent Pipeline Updates, H1 2014 264
Tuberculosis - Dormant Projects, H1 2014 274
Tuberculosis - Discontinued Products, H1 2014 275
List of Figures
Number of Products under Development for Tuberculosis, H1 2014 22
Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 24
Number of Products under Investigation by Universities/Institutes, H1 2014 30
Comparative Analysis by Late Stage Development, H1 2014 34
Comparative Analysis by Clinical Stage Development, H1 2014 35
Comparative Analysis by Early Stage Products, H1 2014 36
Assessment by Monotherapy Products, H1 2014 100
Number of Products by Top 10 Target, H1 2014 101
Number of Products by Stage and Top 10 Target, H1 2014 102
Number of Products by Top 10 Mechanism of Action, H1 2014 104
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 105
Number of Products by Top 10 Route of Administration, H1 2014 107
Number of Products by Stage and Top 10 Route of Administration, H1 2014 108
Number of Products by Top 10 Molecule Type, H1 2014 109
Number of Products by Stage and Top 10 Molecule Type, H1 2014 110
